These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27771485)

  • 41. A rational approach towards development of amorphous solid dispersions: Experimental and computational techniques.
    Chakravarty P; Lubach JW; Hau J; Nagapudi K
    Int J Pharm; 2017 Mar; 519(1-2):44-57. PubMed ID: 28063904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. smartPearls - Novel physically stable amorphous delivery system for poorly soluble dermal actives.
    Müller RH; Hespeler D; Jin N; Pyo SM
    Int J Pharm; 2019 Jan; 555():314-321. PubMed ID: 30439490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
    Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
    J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
    Aucamp M; Milne M; Liebenberg W
    AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery.
    Al-Obaidi H; Majumder M; Bari F
    Curr Pharm Des; 2017; 23(3):350-361. PubMed ID: 27829335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amorphous-Amorphous Phase Separation in API/Polymer Formulations.
    Luebbert C; Huxoll F; Sadowski G
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28212300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersions on the drug and polymer dissolution rate.
    Higashi K; Hayashi H; Yamamoto K; Moribe K
    Int J Pharm; 2015 Oct; 494(1):9-16. PubMed ID: 26253374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmaceutical co-crystals-an opportunity for drug product enhancement.
    Miroshnyk I; Mirza S; Sandler N
    Expert Opin Drug Deliv; 2009 Apr; 6(4):333-41. PubMed ID: 19348603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aspartame as a co-former in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
    Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and solution stability evaluation.
    Ali AM; Ali AA; Maghrabi IA
    Acta Pharm; 2015 Jun; 65(2):133-46. PubMed ID: 26011930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with Naproxen and Cinnarizine.
    Kayaert P; Van den Mooter G
    Eur J Pharm Biopharm; 2012 Aug; 81(3):650-6. PubMed ID: 22579733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram.
    Pajula K; Taskinen M; Lehto VP; Ketolainen J; Korhonen O
    Mol Pharm; 2010 Jun; 7(3):795-804. PubMed ID: 20361760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of copolymer composition on the phase behavior of solid dispersions.
    Prudic A; Kleetz T; Korf M; Ji Y; Sadowski G
    Mol Pharm; 2014 Nov; 11(11):4189-98. PubMed ID: 25295846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physical stability of amorphous acetanilide derivatives improved by polymer excipients.
    Miyazaki T; Yoshioka S; Aso Y
    Chem Pharm Bull (Tokyo); 2006 Aug; 54(8):1207-10. PubMed ID: 16880672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P; Puri V; Bansal AK
    Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel approach for analyzing glass-transition temperature vs. composition patterns: application to pharmaceutical compound+polymer systems.
    Kalogeras IM
    Eur J Pharm Sci; 2011 Apr; 42(5):470-83. PubMed ID: 21324354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physical stability of amorphous pharmaceutical solids: Nucleation, crystal growth, phase separation and effects of the polymers.
    Shi Q; Li F; Yeh S; Wang Y; Xin J
    Int J Pharm; 2020 Nov; 590():119925. PubMed ID: 33011255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.